There’s a new king in the domestic drug industry after hopes for a coronavirus treatment helped turbocharge its shares.
Chugai Pharmaceutical Co., the nation’s leading oncology company, is the best performer on the Nikkei 225 this year, up almost 60 percent versus the 2.4 percent drop in the broader index. The surge has brought its market value neck-and-neck with that of electronics giant Sony Corp. to make it the seventh-largest company in the country.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this support page.
We humbly apologize for the inconvenience.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
PHOTO GALLERY (CLICK TO ENLARGE)
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.